Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Peginterferon/Ribavirin Cost Balanced By Increased Efficacy - Schering

Executive Summary

Cost-effectiveness arguments will likely underpin European marketing of Schering-Plough's ViraferonPeg in combination with Rebetol for treatment of chronic hepatitis C, and could be used in U.S. marketing when the combination is approved by FDA.
Advertisement

Related Content

Pegasys Individualized Dosing To Be Studied As EU Postmarket Commitment
Pegasys Individualized Dosing To Be Studied As EU Postmarket Commitment
Schering PEG-Intron/Rebetol Phase IV To Evaluate Alternate Dosing Regimen
Schering PEG-Intron/Rebetol Phase IV To Evaluate Alternate Dosing Regimen
Advertisement
UsernamePublicRestriction

Register

PS037598

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel